Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Intellia Therapeutics
About
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
- Cambridge,Massachusetts,United States
- 501 - 1000
- http://intelliatx.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $300M
- Industries
- Biotechnology,Genetics,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2014
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
- Stock Symbol
- nasdaq:NTLA
- Legal Name
- Intellia Therapeutics, Inc.
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex Vivo, and in vivo approaches. Intellia Therapeutics was formed in 2014 and is headquartered in Cambridge, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 30, 2022 | Post-IPO Equity | $300M | — | — | — | Detail |
| Jun 30, 2021 | Post-IPO Equity | $690M | — | — | — | Detail |
| Nov 1, 2017 | Post-IPO Equity | $150M | — | — | — | Detail |
| May 6, 2016 | IPO | $108M | — | — | — | Detail |
| Sep 1, 2015 | Series B | $70M | 8 |
OrbiMed
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 26, 2022
Kyverna Therapeutics
|
Series B | $85M | Biotechnology | — |
|
Oct 13, 2021
SparingVision
|
Corporate Round | — | Biotechnology | Yes |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
OrbiMed
|
Yes | Series B |
Atlas Venture
|
— | Series B |
|
|
— | Series B |
Fidelity Management and Research Company
|
— | Series B |
|
|
— | Series B |
Janus Capital Group
|
— | Series B |
Novartis
|
— | Series B |
Sectoral Asset Management
|
— | Series B |
Caribou Biosciences
|
— | Series A |
Employee Profiles
Acquisition
Intellia Therapeutics has acquired 1 organizations. Their most recent acquisition was Rewrite Therapeutics on Feb 3, 2022. They acquired Rewrite Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Feb 3, 2022
Rewrite Therapeutics
|
Biotechnology | acquisition | — | Detail |
